Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Ward

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Urologic Oncology|March 7, 2021
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensusWei Phin Tan, Ardeshir R Rastinehad, Laurence Klotz, et al.
European Urology|June 14, 2020
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary ConsensusAmir H Lebastchi, Arvin K George, Thomas J Polascik, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Urologic Oncology|August 2, 2015
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial designWillemien van den Bos, Berrend G Muller, Daniel M de Bruin, et al.
European Urology Focus|November 17, 2024
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter StudyAlireza Ghoreifi, Farshad Sheybaee Moghaddam, Anirban P Mitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Urologic Oncology|March 7, 2021
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensusWei Phin Tan, Ardeshir R Rastinehad, Laurence Klotz, et al.
European Urology|June 14, 2020
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary ConsensusAmir H Lebastchi, Arvin K George, Thomas J Polascik, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Urologic Oncology|August 2, 2015
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial designWillemien van den Bos, Berrend G Muller, Daniel M de Bruin, et al.
European Urology Focus|November 17, 2024
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter StudyAlireza Ghoreifi, Farshad Sheybaee Moghaddam, Anirban P Mitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
Pageof 11